Search
Ipecac
go.drugbank.com/drugs/DB13293ApprovedWithdrawn[L2753] Ipecac was approved by Health Canada as an OTC but all those products are now discontinued. … use to cause vomiting in poisoning.
Dalbavancin
go.drugbank.com/drugs/DB06219ApprovedInvestigationalDalbavancin acts by interfering with bacterial cell wall synthesis by binding to the D-alanyl-D-alanine terminus of nascent cell wall peptidoglycan and preventing cross-linking [FDA Label, F2356, A4072 … Modifications from these older glycoprotein classes facilitated a similar mechanism of action for dalbavancin but with increased activity and once-weekly dosing [FDA Label, F2356, A4072, A4073].
Liothyronine
go.drugbank.com/drugs/DB00279ApprovedInvestigationalVet approved[T457] The exogenous liothyronine product was developed by King Pharmaceuticals and FDA approved in 1956.[L5578] … Liothyronine is a thyroidal hormone T3 which is normally produced by the thyroid gland in a ratio 4:1 when compared with T4: T3.
Mixtures: Np Thyroid 90, NP Thyroid 30Categories: Agents used to treat hypothyroidismDrometrizole trisiloxane
go.drugbank.com/drugs/DB11585ApprovedThe compound is a lipophilic benzotriazole derivative marketed as Meroxyl XL by L'Oreal, although sunscreens with drometrizole trisiloxane are currently only approved for use in the EU, Canada, Australia … Despite being used elsewhere in the world with relatively few reports of adverse reactions, the FDA continues to cite that the existing scientific record is not sufficient to establish the compound as
Mixtures: Garnier Ombrelle SPF 30 UVA UVB Kids Wet N Protect Sunscreen Protection Even on Wet Skin Hypoallergenic Water/sweat resistant 80 minutes Quick Absorption, Garnier Ombrelle SPF 60 UVA UVB Kids Wet N Protect Sunscreen Protection Even on Wet Skin Hypoallergenic Water/sweat resistant 80 minutes Quick AbsorptionAlbutrepenonacog alfa
go.drugbank.com/drugs/DB13884Approved[A32547] It was developed by CSL Behring Canada, Inc and approved by Health Canada on April 26, 2017. It was also approved by FDA and EMA in 2016.
Imetelstat
go.drugbank.com/drugs/DB14909ApprovedInvestigational[erythropoietin]), but primary resistance to these agents is frequent - the median response duration is 18 to 24 months, with most responders (70%) relapsing due to loss of sensitivity of erythroid progenitors … [A263973] It is used to treat anemia in patients with myelodysplastic syndromes (MDS), a group of hematologic disorders characterized by ineffective hematopoiesis, peripheral cytopenia, abnormal marrow
Vaborbactam
go.drugbank.com/drugs/DB12107ApprovedInvestigationalVaborbactam is added to the therapy to reduce the extent meropenem degradation by inhibiting the serine beta-lactamases expressed by the microorganism of target. … [Label] The treatment aims to resolve infection-related symptoms of cUTI and achieve negative urine culture, when the infections are proven or strongly suspected to be caused by susceptible bacteria.
Voriconazole
go.drugbank.com/drugs/DB00582ApprovedInvestigational[A236050] Voriconazole was approved by the FDA under the trade name Vfend on May 24, 2002.[L34660] … Voriconazole (Vfend, Pfizer) is a triazole antifungal medication used to treat serious fungal infections.
Semaglutide
go.drugbank.com/drugs/DB13928ApprovedInvestigationalSemaglutide works by binding to and activating the GLP-1 receptor, thereby stimulating insulin secretion and reducing blood glucose. … Semaglutide was developed by Novo Nordisk and approved by the FDA for subcutaneous injection in December 2017.[L8681] The tablet formulation was approved for oral administration in September 2019.
Palovarotene
go.drugbank.com/drugs/DB05467ApprovedIt first garnered interest as a potential treatment for emphysema but was eventually recognized as a potential novel therapy for patients with FOP. … [L40010] On August 16, 2023, palovarotene was also approved by the FDA for the management of HO associated with FOP.[L47845]